tradingkey.logo

enVVeno Medical Corp

NVNO
查看详细走势图
0.355USD
+0.013+3.74%
收盘 12/24, 13:00美东报价延迟15分钟
7.17M总市值
亏损市盈率 TTM

enVVeno Medical Corp

0.355
+0.013+3.74%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.74%

5天

+2.93%

1月

+2.75%

6月

-91.47%

今年开始到现在

-88.25%

1年

-87.42%

查看详细走势图

TradingKey enVVeno Medical Corp股票评分

单位: USD 更新时间: 2025-12-24

操作建议

enVVeno Medical Corp当前公司基本面数据相对谨慎,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名211/404位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价12.50。中期看,股价处于下降通道。近一个月,市场表现一般,基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间,可以做区间波段操作。

enVVeno Medical Corp评分

相关信息

行业排名
211 / 404
全市场排名
379 / 4562
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 1 位分析师
持有
评级
12.500
目标均价
+1517.29%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

enVVeno Medical Corp亮点

亮点风险
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
估值高估
公司最新PE估值-0.33,处于3年历史高位
机构减仓
最新机构持股5.69M股,环比减少10.50%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值29.20K
活跃度增加
近期活跃度增加,过去20天平均换手率8.32

enVVeno Medical Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

enVVeno Medical Corp简介

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
公司代码NVNO
公司enVVeno Medical Corp
CEOBerman (Robert A)
网址https://envveno.com/

常见问题

enVVeno Medical Corp(NVNO)的当前股价是多少?

enVVeno Medical Corp(NVNO)的当前股价是 0.355。

enVVeno Medical Corp的股票代码是什么?

enVVeno Medical Corp的股票代码是NVNO。

enVVeno Medical Corp股票的52周最高点是多少?

enVVeno Medical Corp股票的52周最高点是5.620。

enVVeno Medical Corp股票的52周最低点是多少?

enVVeno Medical Corp股票的52周最低点是0.301。

enVVeno Medical Corp的市值是多少?

enVVeno Medical Corp的市值是7.17M。

enVVeno Medical Corp的净利润是多少?

enVVeno Medical Corp的净利润为-21.82M。

现在enVVeno Medical Corp(NVNO)的股票是买入、持有还是卖出?

根据分析师评级,enVVeno Medical Corp(NVNO)的总体评级为持有,目标价格为12.500。

enVVeno Medical Corp(NVNO)股票的每股收益(EPS TTM)是多少

enVVeno Medical Corp(NVNO)股票的每股收益(EPS TTM)是-1.078。
KeyAI